Biotech Catalyst Calendar — August 30, 2026

Trial readouts with primary completion between 2026-08-30 and 2026-10-31, as the registry stood on 2026-08-30. 476 industry-sponsored Phase 2/3 trials · 124 firm · 156 soft · 163 speculative.

100% of these dates are the sponsor's own estimate. Every forward-looking completion date in the registry is — a date becomes "actual" only after the completion happens — which is why this calendar grades the dates rather than simply listing them. 63.4% name a day; the rest give only a month.

Landing in the next 30 days

The 19 late-stage readouts due within 30 days that also carry a firm date. Roche, Bayer, GSK, Biogen and Boehringer Ingelheim all appear; the earliest three are due tomorrow.

Phase 3 — 157 trials

Phase 2/3 — 20 trials

Phase 2 — 170 trials

10 more Phase 2 trials in this window are not shown.

Phase 1/2 — 96 trials

Kept off the calendar

Six trials in this window are withdrawn or suspended and are not catalysts. They are listed here rather than dropped, because their exclusion is the evidence the confidence grade is honest:

Note what every withdrawn row has in common: enrolment of zero, reported as ACTUAL. Completed enrolment is otherwise the strongest evidence that a completion date will hold — so a confidence score that rewarded "actual enrolment" without first checking the trial's status would rate all five of these dead trials as the most credible dates on the page. The status gate runs first for exactly that reason.

A further 27 trials were excluded for enrolling fewer than 20 participants.

What this window is concentrated in

Ten trials in breast cancer, six each in non-small-cell lung cancer, systemic lupus erythematosus and type 2 diabetes, five each in atopic dermatitis and obesity. A trial lists several conditions, so these counts sum to more than the number of trials.

The busiest sponsors are Hoffmann-La Roche (10 trials in the window), AstraZeneca and GlaxoSmithKline (9 each), then Bristol-Myers Squibb, Incyte and Innovent Biologics (6 each).

---

How this is built. Source: ClinicalTrials.gov API v2 (https://clinicaltrials.gov/) — free, keyless and official. The window is every INTERVENTIONAL trial with an INDUSTRY lead sponsor and a Phase 2 or Phase 3 designation whose primary completion date falls in the 62 days from 2026-08-30.

Every date here is an estimate. A completion date becomes "actual" only after the completion happens, so 100% of any forward calendar is the sponsor's projection. The confidence grade (0–100) is how much the DATE is worth believing, not how likely the trial is to succeed: enrolment closed with a real participant count (40), how far the trial has progressed (25), whether the sponsor named a day rather than a month (20), and how recently the record was revised (15). 70+ is firm, 40+ soft, below that speculative.

Excluded and reported separately: withdrawn, suspended and terminated trials; trials with no primary completion date; and trials below 20 participants. Phase 1/2 trials are labelled as such rather than counted as Phase 2 — the registry encodes them as both.

What this feed does not have: PDUFA goal dates and FDA advisory committee dates (the FDA publishes no machine-readable calendar of either, and a PDUFA date becomes public only when the sponsor announces it), and company tickers (the registry carries no security identifier). Rubric biotech-catalysts/v1. Not investment advice.